SOUTH SAN FRANCISCO, Calif., March 12, 2015 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its fourth quarter and full-year 2014 financial results after close of market on Thursday, March 19, 2015. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and business progress.
The live webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live webcast to ensure adequate time for any necessary software download. Alternatively, please call (855) 541-0980 (U.S.) or (970) 315-0440 (international) to listen to the live conference call. The conference ID number for the live call is 3080146. Please dial in approximately 10 minutes prior to the call. The webcast will be available on the company's website approximately two hours following completion of the call for 14 days.
About Veracyte
Veracyte (Nasdaq: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's first commercial solution, the Afirma® Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment, since its launch in 2011. As of September 30, 2014, Veracyte estimates its Afirma
solution has helped approximately 10,000 patients with thyroid nodules avoid unnecessary surgery, reducing healthcare costs by millions of dollars. Afirma is recommended in leading practice guidelines and is covered for more than 140 million lives in the United States, including through Medicare and most commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. The company expects to launch the Percepta™ Bronchial Genomic Classifier, a test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer, in 2015. Veracyte is also developing a second product in pulmonology, targeting
interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.
Veracyte, Afirma, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.
Media:
Tracy Morris
650-380-4413
tracy.morris@veracyte.com
Investors:
Ami Bavishi
Burns McClellan, Inc.
212-213-0006
abavishi@burnsmc.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/veracyte-inc-to-announce-fourth-quarter-and-full-year-2014-financial-results-and-host-conference-call-and-webcast-on-thursday-march-19-2015-300049461.html
SOURCE Veracyte